Previous Article | Next Article ![]()
Journal of Clinical Microbiology, January 2001, p. 274-278, Vol. 39, No. 1
Laboratoire de Microbiologie
Médicale1 and Département
d'Information Médicale,3 Institut Jean
Godinot, 51056 Rheims Cedex, and Laboratoire de
Microbiologie Médicale, Institut Curie, 75231 Paris Cedex
05,2 France
Received 3 April 2000/Returned for modification 1 September
2000/Accepted 31 October 2000
We carried out a prospective study in two French Comprehensive
Cancer Centers (95 and 184 beds, respectively) to assess the validity
of a test based on the earlier positivity of central venous blood
cultures in comparison with peripheral blood cultures for predicting
catheter-related bacteremia. The differences between the times to
positivity for the 21 patients with clinical catheter-related bacteremia and the differences between the times to positivity for the
nine patients with bacteremia due to another source were compared by
the median test. The difference between the median values was
significant (P = 0.0003). A receiver operating
characteristic curve was constructed to determine the optimum threshold
of the test, which appeared to be at the cutoff point of
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.1.274-278.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Validity of Earlier Positivity of Central Venous Blood Cultures
in Comparison with Peripheral Blood Cultures for Diagnosing
Catheter-Related Bacteremia in Cancer Patients
+3 h, with 100% specificity and 81% sensitivity. The positive and negative predictive values obtained with this cutoff point confirmed the efficacy of the test for predicting the presence or absence of catheter-related bacteremia in cancer patients. The cutoff point was
then used to post-classify the 68 episodes of bacteremia from an
unknown source. The characteristics and clinical course of both the
positive and negative post-classified episodes did not show that the
test was clearly useful for a large number of clinical presentations.
We therefore suggest restricting it to febrile neutropenic cancer
patients for whom clinical signs of infection are slight or absent and
when the test is positive.
*
Corresponding author. Mailing address: Laboratoire de
Microbiologie, Institut Jean Godinot, 1 rue du Général
Koenig, BP 171, 51056 Rheims Cedex, France. Phone: 33 3 26 50 42 93. Fax: 33 3 26 50 42 94. E-mail:
veronique.bussy{at}reims.fnclcc.fr.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»